GP369, an FGFR2-IIIb–Specific Antibody, Exhibits Potent Antitumor Activity against Human Cancers Driven by Activated FGFR2 Signaling-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

GP369, an FGFR2-IIIb–Specific Antibody, Exhibits Potent Antitumor Activity against Human Cancers Driven by Activated FGFR2 Signaling

Published:2010-08-13 Issue:19 Volume:70 Page:7630-7639
ISSN:0008-5472
Container-title:Cancer Research
language:en
Short-container-title:Cancer Res

Author:

Bai Ailin,Meetze Kristan,Vo Nhi Y.,Kollipara Sriram,Mazsa Elizabeth K.,Winston William M.,Weiler Solly,Poling Laura L.,Chen Ting,Ismail Nesreen S.,Jiang Jinwei,Lerner Lorena,Gyuris Jeno,Weng Zhigang

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 126 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Persistent response to combination treatment of pemigatinib and chemotherapy in a patient with advanced gastric cancer: A case report;Malignancy Spectrum;2024-07-25

2. Targeting FGFR for cancer therapy;Journal of Hematology & Oncology;2024-06-03

3. Clinical Developments and Challenges in Treating FGFR2-Driven Gastric Cancer;Biomedicines;2024-05-17

4. FGFR and inhibitors;Fibroblast Growth Factors;2024

5. Growth factors reviews;Fibroblast Growth Factors;2024

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP